| |
Article Title |
Author(s) |
Pages |
|
|
|
Contributors
|
|
iii-iv
|
|
|
|
Contents
|
|
v-vii
|
|
|
|
CME Accreditation Page and Author Disclosure
|
|
viii
|
|
|
|
Forthcoming Issues
|
|
ix
|
|
|
|
Foreword
Starting this year, I have agreed to take over as Consulting Editor for the Urologic Clinics. Many of you know that this position was previously held by Martin Resnick, someone who I considered to be ...
|
Samir S. Taneja
|
xi-xii
|
|
|
|
Evolving Treatment Paradigms for Renal Cancer
12 March 2012
Over the past decade there have been steady advancements in the diagnosis, understanding, and management of renal cancers. While the mainstay of urologic therapy for both early- and late-stage disease...
|
William C. Huang,
Samir S. Taneja
|
xiii-xiv
|
|
|
|
Histologic Variants of Renal Cell Carcinoma: Does Tumor Type Influence Outcome?
09 March 2012
Each histologic type of renal cell carcinoma (RCC) has different pathologic and clinical parameters; however, the independent role of histologic type in outcome prediction remains contested. Most stud...
|
Fang-Ming Deng,
Jonathan Melamed
|
119-132
|
|
|
|
The Surgical Approach to Multifocal Renal Cancers: Hereditary Syndromes, Ipsilateral Multifocality, and Bilateral Tumors
24 February 2012
Although the management of sporadic renal tumors is challenging enough, dealing with those with bilateral, multifocal, and hereditary kidney cancer adds an additional level of complexity. A clinician ...
|
Brian Shuch,
Eric A. Singer,
Gennady Bratslavsky
|
133-148
|
|
|
|
Current Practice Patterns in the Surgical Management of Renal Cancer in the United States
05 March 2012
Over the last two decades, there has been a rising incidence of renal tumors, particularly, small renal masses (<4 cm) resulting in a downward size and stage migration. This has brought about a par...
|
Ganesh Sivarajan,
William C. Huang
|
149-160
|
|
|
|
Contemporary Imaging of the Renal Mass
01 March 2012
Contemporary imaging techniques for renal mass evaluation are essential to clinical management and surgical planning. Ultrasonography can be used to distinguish cystic from solid lesions but is less s...
|
Stella K. Kang,
Hersh Chandarana
|
161-170
|
|
|
|
Approach to the Small Renal Mass: to Treat or Not to Treat
22 February 2012
Accurately conveying the benefits and risks of treatment interventions to patients diagnosed with small renal masses (SRMs) is essential to appropriately identify which patients will achieve better on...
|
Simon P. Kim,
R. Houston Thompson
|
171-179
|
|
|
|
Does Renal Mass Ablation Provide Adequate Long-term Oncologic Control?
17 February 2012
Renal ablation (RA) is no longer used exclusively in patients with limited life expectancy. There are few studies reporting a minimum follow-up of 5 years. Biases and discrepancies within the literatu...
|
Stephen Faddegon,
Jeffrey A. Cadeddu
|
181-190
|
|
|
|
The Influence of Surgical Approach to the Renal Mass on Renal Function
16 February 2012
The National Kidney Foundation estimates that 26 million Americans are living with chronic kidney disease (CKD). The high prevalence of obesity, heart disease, hypertension, and diabetes places millio...
|
Brian R. Lane,
Christopher M. Whelan
|
191-198
|
|
|
|
Partial Nephrectomy: Contemporary Outcomes, Candidate Selection, and Surgical Approach
Localized kidney cancer is ideally managed with surgical extirpation. Historically renal cell carcinoma has been treated with radical nephrectomy, but partial nephrectomy has become increasingly used ...
|
Emil Kheterpal,
Samir S. Taneja
|
199-210
|
|
|
|
Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma
Proper integration of surgery and systemic therapy is essential for improving outcomes in renal cell carcinoma (RCC). There is no current role for adjuvant therapy after nephrectomy for clinically loc...
|
Patrick A. Kenney,
Christopher G. Wood
|
211-231
|
|
|
|
Defining an Individualized Treatment Strategy for Metastatic Renal Cancer
02 March 2012
Treatment of metastatic renal cell carcinoma (mRCC) has evolved dramatically within the past 10 years with the advent of therapy targeting the angiogenesis and mammalian target of rapamycin (mTOR) pat...
|
Brian Hu,
Primo N. Lara,
Christopher P. Evans
|
233-249
|
|
|
|
Index
|
|
251-256
|
|
